

CURRENT PROTOCOLS IN MOLECULAR BIOLOGY



VOLUME 2

EDITORIAL BOARD

Frederick M. Ausubel
Massachusetts General Hospital & Harvard Medical School

Roger Brent
The Molecular Sciences Institute, Berkeley, California

Robert E. Kingston
Massachusetts General Hospital & Harvard Medical School

David D. Moore
Baylor College of Medicine

J.G. Seidman
Harvard Medical School

John A. Smith
University of Alabama at Birmingham

Kevin Struhl
Harvard Medical School

GUEST EDITORS

Lisa M. Albright
DNA Sequencing

Donald M. Coen
Harvard Medical School
Polymerase Chain Reaction


Ajit Varki
University of California San Diego
Glycoproteins

SERIES EDITOR

Virginia Benson Chanda



John Wiley & Sons, Inc.



CORE 14 (S41)

Copyright © 1994-1998 by John Wiley & Sons, Inc.

Copyright © 1987-1994 by Current Protocols

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

While the authors, editors, and publisher believe that the specification and usage of reagents, equipment, and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they accept no legal responsibility for any errors or omissions, and make no warranty, express or implied, with respect to material contained herein. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. This is particularly important in regard to new or infrequently employed chemicals or experimental reagents.

Library of Congress Cataloging in Publication Data:

Current protocols in molecular biology. 3 vols.

1. Molecular biology—Technique. 2. Molecular biology—Laboratory manuals. I. Ausubel, Frederick M.

QH506.C87 1987 574.8'8'028 87-21033
ISBN 0-471-50338-X

Printed in the United States of America

20 19 18 17 16 15 14

Enzyme-Linked Immunosorbent Assays (ELISA)

UNIT 11.2

This unit describes six different ELISA systems for the detection of specific antibodies, soluble antigens, or cell-surface antigens. In all six systems, soluble reactants are removed from solution after specifically binding to solid-phase reactants. Table 11.2.1 summarizes the different ELISA protocols, which are illustrated in Figures 11.2.1-11.2.6.

In the first four protocols, solid-phase reactants are prepared by adsorbing an antigen or antibody onto plastic microtiter plates; in the next two protocols, the solid-phase reactants are cell-associated molecules. In all protocols, the solid-phase reagents are incubated with secondary or tertiary reactants covalently coupled to an enzyme.

Table 11.2.1 Summary of ELISA Protocols

ELISA protocol	Uses	Required reagents	Comments
Indirect	Antibody screening; epitope mapping	Antigen, pure or semipure; test solution containing antibody; enzyme conjugate that binds Ig of immunized species	Does not require the use of preexisting specific antibodies; requires relatively large amounts of antigen
Direct competitive	Antigen screening; detect soluble antigen	Antigen, pure or semipure; test solution containing antigen; enzyme-antibody conjugate specific for antigen	Rapid assay with only two steps; excellent for measuring antigenic cross-reactivity
Antibody-sandwich	Antigen screening; detect soluble antigen	Capture antibody (purified or semi-purified specific antibody); test solution containing antigen; enzyme-antibody conjugate specific for antigen	Most sensitive antigen assay; requires relatively large amounts of pure or semi-pure specific antibody (capture antibody)
Double antibody-sandwich	Antibody-screening; epitope mapping	Capture antibody: (specific for Ig of immunized species); test solution containing antigen; enzyme-antibody conjugate specific for antigen	Does not require purified antigen; relatively long assay with five steps
Direct cellular	Screen cells for expression of antigen; measure cellular antigen expression	Cells that express antigen of interest; enzyme-antibody conjugate specific for cellular antigen	Sensitive assay for bulk screening; insensitive to heterogeneity of expression in mixed population of cells
Indirect cellular	Screen for antibodies against cellular antigens	Cells used for immunizing; test solution containing antibodies; enzyme conjugate that binds Ig of immunized species	May not detect antibodies specific for cellular antigens expressed at a low density

Immunology

11.2.1

**BASIC
PROTOCOL**

Unbound conjugates are washed out and a chromogenic or fluorogenic substrate is added. As the substrate is hydrolyzed by the bound enzyme conjugate, a colored or fluorescent product is generated. Finally, the product is detected visually or with a microtiter plate reader. The amount of product generated is proportional to the amount of analyte in the test mixture. The first support protocol can be used to optimize the different ELISAs. The second support protocol provides a method for preparing lysates for use as test antigen from bacterial cultures containing expressed protein.

INDIRECT ELISA TO DETECT SPECIFIC ANTIBODIES

This assay is useful for screening antisera or hybridoma supernatants for specific antibodies when milligram quantities of purified or semipurified antigen are available (1 mg of purified antigen will permit screening of 80 to 800 microtiter plates; Fig. 11.2.1). Antibodies are detected by coating the wells of microtiter plates with antigen, incubating the coated plates with test solutions containing specific antibodies, and washing away unbound antibodies. A solution containing a developing reagent, (e.g., alkaline phosphatase conjugated to protein A, protein G, or antibodies against the test solution antibodies) is then added to the plate. After incubation, unbound conjugate is washed away and substrate solution is added. After a second incubation, the amount of substrate hydrolyzed is assessed with a spectrophotometer or spectrofluorometer. The measured amount is proportional to the amount of specific antibody in the test solution. Visual inspection can also be used to detect hydrolysis.

Materials

Developing reagent: protein A–alkaline phosphatase conjugate (Sigma #P9650), protein G–alkaline phosphatase conjugate (Calbiochem #539304), or anti-IgG alkaline phosphatase conjugate (*UNIT 11.1*)

Antigen solution

PBS (*APPENDIX 2*) containing 0.05% NaN₃ (PBSN)

Water, deionized or distilled

Blocking buffer

Test antibody samples

4-methylumbelliferyl phosphate (MUP) or *p*-nitrophenyl phosphate (NPP) substrate solution

0.5 M NaOH (optional)

Multichannel pipet and disposable pipet tips

Immulon 2 (Dynatech #011-010-3450), Immulon 4 (Dynatech #011-010-3850), or equivalent microtiter plates

Plastic squirt bottles

Microtiter plate reader (optional)—spectrophotometer with 405-nm filter or spectrofluorometer (Dynatech #011-970-1900) with 365-nm excitation filter and 450-nm emission filter

Determine developing reagent and antigen concentrations

1. Determine the optimal concentration of the developing reagent (conjugate) by criss-cross serial dilution analysis (see first support protocol).

Good conjugates of many specificities are available commercially. Choice of developing reagent (i.e., conjugate) is determined by the goals of the assay. If it is necessary to detect all antibodies that bind to antigen, conjugates prepared with antibodies specific for Ig κ and λ light chains should be used. Alternatively, protein A– or protein G–enzyme conjugates may be preferable when screening monoclonal antibodies. Specific monoclonal antibodies that bind protein A or protein G are easy to purify and characterize.

2. Determine the final concentration of antigen coating reagent by criss-cross serial dilution analysis (see first support protocol). Prepare an antigen solution in PBSN at this final concentration. The final concentration of antigen is usually 0.2 to 10.0 $\mu\text{g/ml}$. Prepare ~6 ml antigen solution for each plate.

Pure antigen solution concentrations are usually $\leq 2 \mu\text{g/ml}$. Although pure antigen preparations are not essential, >3% of the protein in the antigen solution should be the antigen. The total concentration of protein in the antigen solution should be increased for semipurified antigen preparations. Do not raise the total protein concentration in the antigen solution to >10 $\mu\text{g/ml}$, since this concentration usually saturates >85% of the available sites on Immulon microtiter plates. For some antigens, coating may occur more efficiently at different pHs.

Coat plate with antigen

3. Using a multichannel pipet and tips, dispense 50 μl antigen solution into each well of an Immulon microtiter plate. Tap or shake the plate to ensure that the antigen solution is evenly distributed over the bottom of each well.




Figure 11.2.1 Indirect ELISA to detect specific antibodies. Ag = antigen; Ab = antibody; E = enzyme.

4. Wrap coated plates in plastic wrap to seal and incubate overnight at room temperature or 2 hr at 37°C.

Individual adhesive plate sealers are sold commercially but plastic wrap is easier to use and works as well. Sealed plates can be stored at 4°C with antigen solution for months.

5. Rinse coated plate over a sink by filling wells with deionized or distilled water dispensed either from a plastic squirt bottle or from the tap. Flick the water into the sink and rinse with water two more times, flicking the water into the sink after each rinse.

Block residual binding capacity of plate

6. Fill each well with blocking buffer dispensed as a stream from a squirt bottle and incubate 30 min at room temperature.

Residual binding capacity of the plate is blocked in this step. Tween 20 (0.05%) by itself is more effective at blocking than any protein tested, but because the combination of protein and Tween 20 may be more effective than Tween 20 alone in some cases, bovine serum albumin (BSA; 0.25%) is included in the blocking buffer.

7. Rinse plate three times in water as in step 5. After the last rinse, remove residual liquid by wrapping each plate in a large paper tissue and gently flicking it face down onto several paper towels laying on the benchtop.

Rinsing with water is cheaper and easier than rinsing with buffered solutions and is as effective.

Add antibody to plate

8. Add 50 µl antibody samples diluted in blocking buffer to each of the coated wells, wrap plate in plastic wrap, and incubate ≥2 hr at room temperature.

While enough antibody may be bound after 1 to 2 hr to generate a strong signal, equilibrium binding is generally achieved after 5 to 10 hr. Thus, the specific signal may be significantly increased by longer incubations.

For this and all steps involving the delivery of aliquots of many different solutions to microtiter plates with multichannel pipets, such as the primary screening of hybridoma supernatants, the same pipet tips can be reused for hundreds of separate transfers. Wash tips between transfers by expelling any liquid remaining in the tips onto an absorbent surface of paper tissues, rinsing tips five times in blocking buffer, and carefully expelling any residual liquid from tips onto the tissues. Avoid bubbles in the tips; any tip with intractable bubbles should be replaced.

Wash the plate

9. Rinse plate three times in water as in step 5.
10. Fill each well with blocking buffer, vortex, and incubate 10 min at room temperature.

Plates are vortexed to remove any reagent remaining in the corners of the wells.

11. Rinse three times in water as in step 5. After the final rinse, remove residual liquid as in step 7.

Add developing reagent to plate

12. Add 50 µl developing reagent in blocking buffer (at optimal concentration determined in step 1) to each well, wrap in plastic wrap, and incubate ≥2 hr at room temperature.

The strength of the signal may be increased by longer incubations (see annotation to step 8).

13. Wash plates as in steps 9 to 11.

After final rinsing, plates may be wrapped in plastic wrap and stored for months at 4°C prior to adding substrate.

Add substrate and measure hydrolysis

14. Add 75 µl MUP or NPP substrate solution to each well and incubate 1 hr at room temperature.

15. Monitor hydrolysis qualitatively by visual inspection or quantitatively with a microtiter plate reader (see below). Hydrolysis can be stopped by adding 25 µl of 0.5 M NaOH.

a. Visually, hydrolysis of NPP can be detected by the appearance of a yellow color. If using a microtiter plate reader to measure NPP hydrolysis, use a 405-nm filter.

b. Visually, hydrolysis of MUP can be monitored in a darkened room by illumination with a long-wavelength UV lamp. If using a microtiter plate spectrofluorometer to measure MUP hydrolysis, use a 365-nm excitation filter and a 450-nm emission filter.

The fluorogenic system using the MUP substrate is 10 to 100 times faster than the chromogenic system using NPP. Furthermore, the rate of spontaneous hydrolysis of MUP is much lower than that of NPP.

To detect bound antibodies that are present at low concentration, measure hydrolysis at a later time. To calculate when to measure hydrolysis the second time, remember that the amount of hydrolysis is almost directly proportional to the time of hydrolysis. For example, if the hydrolysis in the wells of interest reads 200 at 1 hr and a reading of 2000 is desired, incubate the plate ~10 hr before taking the second reading.

DIRECT COMPETITIVE ELISA TO DETECT SOLUBLE ANTIGENS

ALTERNATE PROTOCOL

This assay is used to detect or quantitate soluble antigens and is most useful when both a specific antibody and milligram quantities of purified or semipurified antigen are available (Fig. 11.2.2). To detect soluble antigens, plates are coated with antigen and the binding of specific antibody-enzyme conjugates to antigen-coated plates is inhibited by test solutions containing soluble antigen. After incubation with mixtures of the conjugate and inhibitor in antigen-coated wells, unbound conjugate is washed away and substrate is added. The amount of antigen in the test solutions is proportional to the inhibition of substrate hydrolysis and can be quantitated by interpolation onto an inhibition curve generated with serial dilutions of a standard antigen solution.

The direct assay may also be adapted as an indirect assay by substituting specific antibody for specific antibody-enzyme conjugate. The amount of specific antibody bound is then detected using a species-specific or isotype-specific conjugate as a tertiary reactant.

Additional Materials

Specific antibody-alkaline phosphatase conjugate (UNIT 11.1)

Standard antigen solution

Test antigen solutions

Round- or cone-bottom microtiter plates

1. Determine the optimal concentration of coating reagent and antibody-alkaline phosphatase conjugate by criss-cross serial dilution analysis in which the concentrations of both the antigen (coating reagent) and the conjugate (developing reagent) are varied (see first support protocol). Prepare a 2× conjugate solution by diluting the

specific antibody–alkaline phosphatase conjugate in blocking buffer to twice the optimal concentration.

The final concentration is usually 25 to 500 ng antibody/ml. Prepare 3 ml antibody–alkaline phosphatase conjugate for each plate.

2. Coat and block wells of an Immulon microtiter plate with 50 μ l antigen solution as in steps 2 to 7 of the basic protocol.
3. Prepare six 1:3 serial dilutions of standard antigen solution in blocking buffer (see first support protocol for preparation of serial dilutions)—these antigen concentrations will be used in preparing a standard inhibition curve (see step 10).

Antigen concentrations should span the dynamic range of inhibition. The dynamic range of inhibition is defined as that range of inhibitor concentrations wherein changes of inhibitor concentration produce detectable changes in the amount of inhibition. The dynamic range of inhibition is empirically determined in an initial assay in which antigen concentration is typically varied from the micromolar (10^{-6} M) to the picomolar (10^{-12} M) range. For most protein antigens, initial concentration should be ~10 μ g/ml, followed by nine 1:4 serial dilutions in blocking buffer. These antigen dilutions are assayed for their ability to inhibit the binding of conjugate to antigen-coated plates under standard assay conditions. From this initial assay, six 1:3 antigen dilutions spanning the dynamic range of inhibition are selected for further use as standard antigen-inhibitor dilutions. Prepare ≥ 75 μ l of each dilution for each plate to be assayed.

Inhibitor curves are most sensitive in the region of the curve where small changes in inhibitor concentrations produce maximal changes in the amount of inhibition. This




Figure 11.2.2 Direct competitive ELISA to detect soluble antigens. Ag = antigen; Ab = antibody; E = enzyme.

region of the curve normally spans 15% to 85% inhibition. In most systems, this range of inhibition is produced by concentrations of inhibitor between 1 and 250 ng/ml.

4. Mix and incubate conjugate and inhibitor by adding 75 μ l of 2 \times conjugate solution (from step 1) to each well of a round- or cone-bottom microtiter plate, followed by 75 μ l inhibitor—either test antigen solution or standard antigen solution (from step 3). Mix the conjugate and inhibitor solutions by pipetting up and down in the pipet tip three times (see annotation to step 8 in the basic protocol) and incubate \geq 30 min at room temperature.

For accurate quantitation of the amount of antigen in the test solutions, test antigen solutions should inhibit conjugate binding between 15% to 85%. It may be necessary to assay two or three different dilutions of the test solutions to produce inhibitions within this range.

5. Prepare uninhibited control samples by mixing equal volumes of 2 \times conjugate solution and blocking buffer.
6. Transfer 50 μ l of the mixture of conjugate plus inhibitor (from step 4) or conjugate plus blocking buffer (from step 5) to an antigen-coated plate (from step 2) and incubate 2 hr at room temperature.

If samples are to be assayed in duplicate, the duplicates should be in adjacent columns on the same plate. Reserve column 11 for uninhibited control samples (step 5) and column 12 for substrate alone without any conjugate. If the concentration of antigen in the test samples is to be accurately quantitated, dilutions of homologous antigen solutions (step 3) should be included on each plate.

7. Wash plate as in steps 9 to 11 of the basic protocol.
8. Add 75 μ l of MUP or NPP substrate solution to each well and incubate 1 hr at room temperature.
9. Read plates on the microtiter plate reader after \geq 1 hr, at which time enough substrate has been hydrolyzed in the uninhibited reactions to permit accurate measurement of the inhibition.
10. Prepare a standard antigen-inhibition curve constructed from the inhibitions produced by the dilutions of the standard antigen solutions from step 3. Plot antigen concentration on the x axis, which is a log scale, and fluorescence or absorbance on the y axis, which is a linear scale.
11. Interpolate the concentration of antigen in the test solutions from the standard antigen-inhibition curve.

The dynamic range of the inhibition curve may deviate from linearity if the specific antibodies are heterogeneous and possess significantly different affinities or if the standard antigen preparation contains heterogeneous forms of the antigen. Antigen concentration in test samples can be accurately interpolated from the inhibition curve as long as the test antigen is antigenically identical to the standard antigen and the concentration of test antigen falls within the dynamic range of inhibition.

ANTIBODY-SANDWICH ELISA TO DETECT SOLUBLE ANTIGENS

Antibody-sandwich ELISAs may be the most useful of the immunosorbent assays for detecting antigen because they are frequently between 2 and 5 times more sensitive than those in which antigen is directly bound to the solid phase (Fig. 11.2.3). To detect antigen, the wells of microtiter plates are coated with specific (capture) antibody followed by incubation with test solutions containing antigen. Unbound antigen is washed out and a different antigen-specific antibody conjugated to enzyme (i.e., developing reagent) is added, followed by another incubation. Unbound conjugate is washed out and substrate is added. After another incubation, the degree of substrate hydrolysis is measured. The amount of substrate hydrolyzed is proportional to the amount of antigen in the test solution.

Additional Materials

Specific antibody or immunoglobulin fraction from antiserum or ascites fluid, *or* hybridoma supernatant (UNIT 11.10), *or* bacterial lysate (second support protocol)




Figure 11.2.3 Antibody-sandwich ELISA to detect antigen. Ag = antigen; Ab = antibody; E = enzyme.

1. Prepare the capture antibody by diluting specific antibody or immunoglobulin fraction in PBSN to a final concentration of 0.2 to 10 µg/ml.

The capture antibodies can be monoclonal or polyclonal.

If the immunoglobulin fraction from an antiserum or ascites fluid is used, the concentration of total protein may need to be increased to compensate for the lower content of specific antibody. Little advantage is gained by increasing the total protein concentration in the capture antibody solution beyond 10 µg/ml.

2. Determine the concentration of capture antibody and conjugate necessary to detect the desired concentration of antigen by criss-cross serial dilution analysis (see first support protocol). Prepare a capture antibody solution in PBSN at this concentration.
3. Coat wells of an Immulon plate with capture-antibody solution as in steps 3 to 5 of the basic protocol.
4. Block wells as in steps 6 and 7 of the basic protocol.
5. Prepare a standard antigen-dilution series by successive 1:3 dilutions of the homologous antigen stock in blocking buffer (see first support protocol).

In order to measure the amount of antigen in a test sample, the standard antigen-dilution series needs to span most of the dynamic range of binding. This range typically spans from 0.1 to 1000 ng antigen/ml. The dynamic range of binding is defined as that range of antigen concentrations wherein small, incremental changes in antigen concentration produce detectable differences in the amount of antigen bound (see annotation to step 3, in the preceding alternate protocol). In most assay systems, the amount of antigen in a test solution is most accurately interpolated from the standard curve if it produces between 15% to 85% of maximal binding.

NOTE: While standard curves are necessary to accurately measure the amount of antigen in test samples, they are unnecessary for qualitative "yes/no" answers.

6. Prepare dilutions of test antigen solutions in blocking buffer.

It may be necessary to assay one or two serial dilutions of the initial antigen test solution to ensure that at least one of the dilutions can be accurately measured. For most assay systems, test solutions containing 1 to 100 ng/ml of antigen can be accurately measured.

7. Add 50-µl aliquots of the antigen test solutions and the standard antigen dilutions (from step 5) to the antibody-coated wells and incubate ≥2 hr at room temperature.

For accurate quantitation, samples should be run in duplicate or triplicate, and the standard antigen-dilution series should be included on each plate (see step 5). Pipetting should be performed rapidly to minimize differences in time of incubation between samples.

8. Wash plate as in steps 9 to 11 of the basic protocol.

9. Add 50 µl specific antibody–alkaline phosphatase conjugate and incubate 2 hr at room temperature.

The conjugate concentration is typically 25 to 400 ng specific antibody/ml.

When the capture antibody is specific for a single determinant, the conjugate must be prepared from antibodies which recognize different determinants that remain available after the antigen is bound to the plate by the capture antibody.

10. Wash plate as in steps 9 to 11 of the basic protocol.

11. Add 75 µl of MUP or NPP substrate solution to each well and incubate 1 hr at room temperature.

**ALTERNATE
PROTOCOL**

12. Read the plate on a microtiter plate reader.
To quantitate low-level reactions, the plate can be read again after several hours of hydrolysis.
13. Prepare a standard curve constructed from the data produced by serial dilutions of the standard antigen (step 5). Plot antigen concentration on the x axis which is a log scale, and fluorescence or absorbance on the y axis which is a linear scale.
14. Interpolate the concentration of antigen in the test solutions from the standard curve.

**DOUBLE ANTIBODY-SANDWICH ELISA TO DETECT
SPECIFIC ANTIBODIES**

This assay is especially useful when screening for specific antibodies in cases when a small amount of specific antibody is available and purified antigen is unavailable (Fig. 11.2.4). Additionally, this method can be used for epitope mapping of different monoclonal antibodies that are directed against the same antigen. Plates are coated with capture antibodies specific for immunoglobulin from the immunized species. The test antibody solution is incubated on the plates coated with the capture antibodies. Plates are then washed, incubated with antigen, washed again, and incubated with specific antibody conjugated to an enzyme. After incubation, unbound conjugate is washed out and substrate is added. Wells that are positive for hydrolysis may contain antibodies specific for the antigen.

Additional Materials

Capture antibodies specific for immunoglobulin from the immunized species
Specific antibody-alkaline phosphatase conjugate

1. Coat wells of an Immulon microtiter plate with 50 µl of 2 to 10 µg/ml capture antibodies as in steps 2 to 5 of the basic protocol.

NOTE: Capture antibodies must not bind the antigen or conjugate antibodies. When analyzing hybridoma supernatants or ascites fluid, coat plates with 2 µg/ml capture antibody. When analyzing antisera, coat plates with 10 µg/ml capture antibody.

2. Block wells as in steps 6 and 7 of the basic protocol.
3. Prepare dilutions of test antibody solutions in blocking buffer. Add 50 µl to coated wells and incubate ≥2 hr at room temperature.

Hybridoma supernatants, antisera, or ascites fluid can be used as the test samples. Dilute hybridoma supernatants 1:5 and antisera or ascites fluid 1:200.

4. Wash plate as in steps 9 to 11 of the basic protocol.
5. Prepare an antigen solution in blocking buffer containing 20 to 200 ng/ml antigen.

Although purified antigen preparations are not essential, the limit of detectability for most protein antigens in this type of system is 2 to 20 ng/ml. A concentration of 20 to 200 ng antigen/ml is recommended.

6. Add 50-µl aliquots of the antigen solution to antibody-coated wells and incubate ≥2 hr at room temperature.
7. Wash plate as in steps 9 to 11 of the basic protocol.
8. Add 50 µl specific antibody-alkaline phosphatase conjugate to the wells and incubate 2 hr at room temperature.

The conjugate antibodies must not react with the capture antibody or the test antibody. The conjugate concentration is typically between 25 to 500 ng specific antibody/ml, and should be high enough to result in ~0.50 absorbance units/hr at 405 nm when using NPP as a substrate or a signal of 1000 to 1500 fluorescence units/hr when using MUP as a substrate. If no specific antibodies from the appropriate species are available to serve as a positive control, then a positive control system should be constructed out of available reagents. Such reagents can be found in Linscott's Directory of Immunological and Biological Reagents.




Figure 11.2.4 Double antibody-sandwich ELISA to detect specific antibodies. Ag = antigen; Ab = antibody; E = enzyme.

9. Wash plate as in steps 9 to 11 of the basic protocol.
 10. Add 75 µl of MUP or NPP substrate solution to each well and incubate 1 hr at room temperature. After 1 hr, examine hydrolysis visually or spectrophotometrically (see step 15 of the basic protocol).
- In order to detect low-level reactions, the plate can be read again after several hours or days of hydrolysis.*
11. Check for false positives by rescreening samples that test positive for antigen-specific antibody. For each positive sample, coat four wells with capture antibody and arm the capture antibody with test antibody (steps 1 to 4). Incubate two of the wells with antigen (steps 5 to 7) and two of the wells with blocking buffer. Add conjugate and substrate to all four wells (steps 8 to 10) and measure hydrolysis after 1 hr.

This procedure will eliminate false positives resulting from test antibodies that react with the enzyme-antibody complex.

ALTERNATE PROTOCOL

DIRECT CELLULAR ELISA TO DETECT CELL-SURFACE ANTIGENS

The expression of cell-surface antigens or receptors is measured using existing antibodies or other ligands specific for cell-surface molecules (Fig. 11.2.5). Cells are incubated with enzyme conjugated to antibodies that are specific for a cell-surface molecule. Unbound conjugate is washed away and substrate is added. The level of antigen expression is proportional to the amount of substrate hydrolysis. This procedure can be as sensitive as flow cytometry analysis in quantitating the level of antigen expression on a population of cells (Coligan et al., 1991). Unlike the flow cytometry analysis, however, this method is not sensitive for mixed populations. This assay can be converted to an indirect assay by substituting biotinylated antibody for the enzyme-antibody conjugate, followed by a second incubation with avidin-alkaline phosphatase.




Figure 11.2.5 Direct cellular ELISA to detect cell-surface antigens. Ab = antibody; E = enzyme; C = cell.

Additional Materials

Cell samples

Specific antibody-alkaline phosphatase conjugate (see second support protocol)

Wash buffer, ice-cold

Cone- or round-bottom microtiter plates

Sorvall H-1000B rotor (or equivalent)

1. Determine the optimal number of cells per well and the antibody-conjugate concentration by criss-cross serial dilution analysis (see first support protocol) using variable numbers of positive- and negative-control cell samples and varying concentrations of antibody-biotin conjugate.

Titrate cells initially at $1-5 \times 10^5$ /well and conjugate at 0.5 to 10 g/ml. For preparation and handling of cells, consult steps 2 to 5.

Because eukaryotic cells express variable amounts of alkaline phosphatase, test cells must be assayed in a preliminary experiment for alkaline phosphatase by incubation with substrate alone. If the test cells express unacceptable levels of alkaline phosphatase, another enzyme conjugate such as β -galactosidase should be used. Both chromogenic and fluorogenic substrates are available for β -galactosidase.

2. Centrifuge cell samples in a table-top centrifuge 5 min in Sorvall H-1000B rotor at 1500 rpm ($450 \times g$), 4°C, in a 15- to 50-ml centrifuge tube. Count cells (APPENDIX 3) and resuspend in ice-cold wash buffer at $1-5 \times 10^6$ cells/ml.

If the surface antigen retains its antigenicity after fixation, cells may be fixed at the beginning of the experiment—but do not fix cells unless it can be demonstrated that the antigenicity is retained after fixation. Fix cells by suspending in glutaraldehyde (0.5% final; from a 25% stock, EM grade Sigma #G5882), and incubating 30 min at room temperature. Pellet cells, resuspend in PBSLE (see second support protocol), and incubate for 30 min at 37°C. Wash twice in PBSLE and resuspend in wash buffer. Cells can be kept for months at 4°C after fixation.

3. Dispense 100 μ l of cell suspension ($1-5 \times 10^5$ cells) into wells of cone- or round-bottom microtiter plates, and centrifuge 1 min at $450 \times g$, 4°C. Remove supernatant by vacuum aspiration, and disrupt pellet by briefly shaking microtiter plate on a vortex mixer or microtiter plate shaker.
4. Resuspend pellet in 100 μ l of conjugate in ice-cold wash buffer at the optimal concentration (see step 1). Incubate 1.5 hr at 4°C, resuspending cells by gently shaking at 15-min intervals.

Be careful not to splash cell suspensions out of wells.

5. Centrifuge cells 1 min at $450 \times g$, 4°C, remove supernatant by vacuum aspiration, briefly vortex pellet, and resuspend in 200 μ l ice-cold wash buffer. Repeat three times.
6. Add 100 μ l MUP or NPP substrate solution. Incubate 1 hr at room temperature, resuspending cells by gently shaking at 15-min intervals during hydrolysis.
7. Determine extent of hydrolysis by visual inspection or using a microtiter plate reader.

INDIRECT CELLULAR ELISA TO DETECT ANTIBODIES SPECIFIC FOR SURFACE ANTIGENS

This assay is designed to screen for antibodies specific for cell-surface antigens (Fig. 11.2.6). Antibodies against surface antigens are detected by incubating whole cells with a test solution containing the primary antibody. The unbound antibody is washed away and the cells are then incubated with an enzyme conjugated to antibodies specific for the primary antibody. Unbound enzyme conjugate is washed away and substrate solution added. The level of bound primary antibody is proportional to the amount of substrate hydrolysis.

Additional Materials

Positive-control antibodies (i.e., those that react with the experimental cells and are from the immunized species)

Negative-control antibodies (i.e., those that do not react with the experimental cells)

Test antibody solution

Antibody or $F(ab')_2$ (against immunoglobulin from the immunized species) conjugated to alkaline phosphatase

Cone- or round-bottom microtiter plates




Figure 11.2.6 Indirect cellular ELISA to detect antibodies specific for surface antigens. Ab = antibody; E = enzyme; C = cell.

1. Centrifuge and resuspend cell samples as in step 2 of the previous alternate protocol at $1\text{-}5 \times 10^6$ cells/ml.

Because this technique detects antibodies against uncharacterized epitopes, fixation prior to analysis is not recommended. Fixation may destroy the antigenicity of the epitope. All steps must be performed at 4°C in physiological buffers containing NaN₃.

Because eukaryotic cells express variable amounts of alkaline phosphatase, test cells must be assayed for alkaline phosphatase activity. If the endogenous alkaline phosphatase level is too high, another enzyme should be substituted for alkaline phosphatase in the antibody-enzyme conjugate (see annotation to step 1 of the previous alternate protocol).

2. In preliminary assays, determine the optimal number of cells per well and conjugate concentration by criss-cross serial dilution analysis using positive- and negative-control antibodies instead of test antibodies (see first support protocol). In adapting the criss-cross serial dilution analysis, whole cells replace the solid-phase coating reagent; see techniques for handling cells are outlined in steps 3 to 8. Set up titrations by varying the number of cells between 1×10^5 and 5×10^5 /well, the concentration of positive- and negative-control antibodies between 0.1 and 10 µg/ml, and the concentration of antibody-enzyme conjugate between 0.1 and 10 µg/ml.
3. Dispense 100 µl of cell suspension ($1\text{-}5 \times 10^5$ cells) into wells of round- or cone-bottom microtiter plates. Centrifuge 1 min at 1500 rpm, 4°C, remove supernatant by vacuum aspiration, and disrupt pellet by briefly shaking microtiter plate on the vortex mixer.
4. Resuspend cells in 100 µl solutions containing 1 to 10 µg/ml test antibody or control antibodies in ice-cold wash buffer. Incubate 1.5 hr at 4°C, resuspending cells by gently shaking at 15-min intervals.

Be careful not to splash cell suspensions out of wells.

5. Centrifuge cells 1 min at 1500 rpm, 4°C, remove supernatant by vacuum aspiration, briefly vortex pellet, and resuspend in 200 µl ice-cold wash buffer. Repeat twice.
6. Resuspend pellet in 100 µl enzyme-antibody conjugate or F(ab')₂-enzyme conjugate diluted in ice-cold wash buffer. The optimal concentration of antibody, determined in step 2, is usually 100 to 500 ng/ml. Incubate 1.5 hr at 4°C, resuspending cells by gently shaking at 15-min intervals.

When working with cells that may express Fc receptors, it is best to use enzyme conjugated to F(ab')₂ fragments. F(ab')₂ fragments have had the Fc portion of the antibody enzymatically removed and no longer bind to Fc receptors.

7. Wash cells as in step 5. Repeat three times.
8. Add 100 µl MUP or NPP substrate solution. Allow hydrolysis to proceed until the signal has reached the desired levels; resuspend cells by gently shaking at 15 min intervals during hydrolysis. If desired, stop hydrolysis by adding 25 µl of 0.5 M NaOH.
9. Determine extent of hydrolysis by visual inspection or spectrophotometrically using a microtiter plate reader.

CRISS-CROSS SERIAL DILUTION ANALYSIS TO DETERMINE
OPTIMAL REAGENT CONCENTRATIONS

Serial dilution titration analyses are performed to determine optimal concentrations of reagents to be used in ELISAs. In this protocol, all three reactants in a three-step ELISA—a primary solid-phase coating reagent; a secondary reagent that binds the primary reagent, and an enzyme-conjugated tertiary developing reagent that binds to the secondary reagent—are serially diluted and analyzed by a criss-cross matrix analysis (Fig 11.2.7). Once the optimal concentrations of reagents to be used under particular assay conditions are determined, these variables are kept constant from experiment to experiment. The coating (primary), secondary, and developing (tertiary) reagents will vary depending upon which of the previous protocols needs to be optimized.

Additional Materials

Coating reagent

Secondary reagent

Developing reagent

17 × 100-mm and 12 × 74-mm test tubes

		Secondary reactant											
		homologous (antigen)						heterologous (antigen)					
Tertiary reactant (antibody-alkaline phosphatase) (ng/ml)	200	50	12.5	3.12	0.78	0	200	50	12.5	3.12	0.78	0	
	over	over	over	3200	1000	0	500	120	40	20	10		A
	over	over	over	2060	560	0	300	80	20	0	0		B
	over	over	3650	1370	360	0	195	40	10	10	0		C
	3600	4000	2270	790	240	0	120	30	10	10	10		D
	2700	2100	1200	410	120	0	60	10	10	10	0		E
	0	0	0	0	0	0	0	0	0	0	0		F
													G
	1	2	3	4	5	6	7	8	9	10	11	12	H
Columns													

Figure 11.2.7 Results of a criss-cross serial dilution analysis (for optimization of secondary and tertiary reactant concentrations) of an antibody-sandwich ELISA to detect antigen. The numbers in columns 1 to 11 and rows B to G represent relative fluorescence units observed for each well on a 96-well microtiter plate.

Plates were coated overnight with the capture antibody at 2 µg/ml. The secondary reactants, 4-fold serial dilutions of the homologous antigen and a non-cross-reactive heterologous antigen, were incubated on the plate 2 hr. The tertiary reactant, 2-fold serial dilutions of specific antibody-alkaline phosphatase conjugates, were incubated on the plate 2 hr. After 1 hr of incubation with the substrate MUP, the fluorescence was read in a microtiter plate spectrofluorometer.

Reagent concentrations depend upon individual assay variables that are set by the investigator. If the time of hydrolysis is set at 1 hr, the relative fluorescence at ~1000 relative fluorescence units, and the sensitivity at 780 pg/ml of homologous antigen, then 500 ng/ml of enzyme-antibody conjugate must be used in the ELISA. If, however, the assay has to detect only 3.12 ng/ml of homologous antigen, then the concentration of conjugate can be reduced to 125 ng/ml. It should be noted by comparing the homologous with the heterologous reactions (wells B5 versus B11 and D4 versus D10) that both the specificity and the signal-to-noise ratio for this assay are excellent.

11.2.16

Prepare coating-reagent dilutions

1. Place four 17×100 -mm test tubes in a rack and add 6 ml PBSN to the last three tubes. In tube 1, prepare a 12-ml solution of coating reagent at 10 $\mu\text{g}/\text{ml}$ in PBSN. Transfer 6 ml of tube 1 solution to tube 2. Mix by pipetting up and down five times. Repeat this transfer and mix for tubes 3 and 4; the tubes now contain the coating reagent at 10, 5, 2.5, and 1.25 $\mu\text{g}/\text{ml}$.
2. Using a multichannel pipet, dispense 50 μl of the coating reagent solutions into wells of four Immulon microtiter plates (i.e., each plate is filled with one of the four dilutions). Incubate overnight at room temperature or 2 hr at 37°C.
3. Rinse and block plates with blocking buffer as in steps 5 to 7 of the basic protocol.

Prepare secondary-reagent dilutions

4. Place five 12×75 -mm test tubes in a rack and add 3 ml blocking buffer to the last four tubes. In tube 1, prepare a 4-ml solution of secondary reagent at 200 ng/ml in PBSN. Transfer 1 ml of tube 1 solution to tube 2. Pipet up and down five times. Repeat this transfer and mix for tubes 3 to 5; the tubes now contain the secondary reactant at 200, 50, 12.5, 3.125, and 0.78 ng/ml. If possible, prepare and test serial dilutions of a nonreactive heterologous form of the secondary reactant in parallel (Fig. 11.2.7).

If the assay is especially insensitive, it may be necessary to increase the secondary reactant concentrations so the tube-1 solution is 1000 ng/ml.

5. Dispense 50 μl of the secondary reagent solutions into the first five columns of all four coated plates. The most dilute solution is dispensed into column 5, while solutions of increasing concentration are added successively into columns 4, 3, 2, and 1. Thus, the fifth column contains 0.78 ng/ml and the first column 200 ng/ml. Incubate 2 hr at room temperature.
6. Wash plates as in steps 9 to 11 of the basic protocol.

Prepare developing-reagent dilutions

7. Place five 17×100 -mm test tubes in a rack and add 3 ml blocking buffer to the last four tubes. In tube 1, prepare a 6-ml solution of developing reagent at 500 ng/ml in blocking buffer. Transfer 3 ml of tube 1 solution into tube 2 and mix. Repeat this transfer and mixing for tubes 3 and 4—the tubes now contain the developing reagent at 500, 250, 125, 62.5, and 31.25 ng/ml.
8. Dispense 50 μl of the developing reagent solutions into the wells of rows 2 to 6 of each plate, dispensing the most dilute solution into row 6 and solutions of increasing concentration successively into rows 5, 4, 3, and 2. Incubate 2 hr at room temperature.
9. Wash plates as in steps 9 to 11 of the basic protocol.

Measure hydrolysis

10. Add 75 μl MUP or NPP substrate solution to each well, incubate 1 hr at room temperature, and measure the degree of hydrolysis visually or with a microtiter plate reader. An appropriate assay configuration results in 0.50 absorbance units/hr at 405 nm when using NPP as a substrate or 1000 to 1500 fluorescence units/hr when using MUP as a substrate.

These results can be used to adjust optimal concentrations in the basic and alternate protocols.

PREPARATION OF BACTERIAL CELL LYSATE ANTIGENS

A culture of *E. coli* containing proteins expressed from cloned genes is lysed for use as test antigen in any of the first three protocols of this unit. For more extensive discussion on protein expression for antigen production, see *UNITS 16.4-16.7* (expression by fusion protein vectors).

Materials

Escherichia coli culture in broth or agar (*UNITS 1.2 & 1.3*)
Cell resuspension buffer
Lysozyme solution
Tris/EDTA/NaCl (TEN) buffer (*UNIT 11.1*)
10% sodium dodecyl sulfate (SDS)
8 M urea (optional)
Nylon-tipped applicator (Falcon #2069, Becton Dickinson)

1. For liquid culture, centrifuge 5 ml of cells at 2500 rpm in a tabletop centrifuge for 10 min. Decant supernatant and resuspend pellet in 5 ml cell resuspension buffer by vortexing gently. For agar culture, remove about 10 colonies from the plate using a nylon-tipped applicator and resuspend in 2 ml cell resuspension buffer. Press swab against side of tube to remove as much liquid as possible.

Yield of expressed protein may vary with growth phase. Samples should be taken for analysis at various periods of growth (e.g., mid-log and stationary phases). If samples are taken from agar plates, the culture should be grown overnight at 37°C.

2. Place 1 ml of resuspended cells in a microcentrifuge tube on ice.
3. Add 0.2 ml lysozyme solution to the tube and leave 5 min on ice.
4. Microcentrifuge 5 min. Decant supernatant and save. Resuspend pellet in 1.2 ml TEN buffer.

Since many expressed proteins are insoluble, it is worthwhile to assay both the pellet and supernatant for activity.

5. Add 0.065 ml of 10% SDS solution to each sample. Incubate 10 min at 37°C. Samples are ready for ELISA at this point. Store frozen if not used within several hours.

Alternatively, add urea to a final concentration of 8 M (4.8 g to a final volume of 10 ml) to denature and solubilize proteins.

REAGENTS AND SOLUTIONS

Borate-buffered saline (BBS)

0.017 M Na₂B₄O₇·10H₂O

0.12 M NaCl

Adjust to pH 8.5 with NaOH

Blocking buffer

BBS (see above) containing:

0.05% Tween 20

1 mM EDTA

0.25% bovine serum albumin (BSA)

0.05% NaN₃

Store at 4°C

Gelatin may be substituted for BSA; 5% instant milk has been successfully used but may interfere nonspecifically with antibody binding.

Cell resuspension buffer (10 mM HEPES)

2.38 g HEPES
Add H₂O to 1 liter

Lysozyme solution

5 mg chicken egg white lysozyme (Sigma Grade VI #L2879)
1 ml TEN buffer (*UNIT 11.1*)
Make fresh immediately before use

MUP substrate solution

0.2 mM 4-methylumbelliferyl phosphate (MUP; Sigma #M8883)
0.05 M Na₂CO₃
0.05 mM MgCl₂
Store at room temperature

NPP substrate solution

3 mM *p*-nitrophenyl phosphate (NPP; Sigma #104-0)
0.05 M Na₂CO₃
0.05 mM MgCl₂
Store at 4°C

Test antibody solution

Hybridoma supernatants (*UNIT 11.10*) can usually be diluted 1:5 and ascites fluid and antisera (*UNIT 11.12*) diluted 1:500 in blocking buffer and still generate a strong positive signal. Dilutions of nonimmune ascites or sera should be assayed as a negative control. Prepare antibody dilutions in cone- or round-bottom microtiter plates before adding them to antigen-coated plates.

Sources of appropriate antibodies and conjugates can be found in Linscott's Directory of Immunological and Biological Reagents.

Test antigen solution

0.2 to 10 µg/ml antigen, purified or partially purified in PBSN; store at 4°C

Wash buffer

Hanks balanced salt solution (HBSS; *APPENDIX 2*)
1% fetal calf serum (FCS; heat-inactivated 60 min, 56°C)
0.05% NaN₃
Store at 4°C

COMMENTARY

Background Information

Since their first description in 1971 (Engvall and Perlman), ELISAs have become the system of choice when assaying soluble antigens and antibodies. Factors that have contributed to their success include their sensitivity, the long shelf-life of the reagents (alkaline phosphatase conjugates typically lose only 5% to 10% of their activity per year), the lack of radiation hazards, the ease of preparation of the reagents, the speed and reproducibility of the assays, and the variety of ELISA formats that can be generated with a few well-chosen reagents. Additionally, no sophisticated equipment is necessary for many ELISA applications, including screening hybridoma supernatants for specific

antibodies and screening biological fluids for antigen content.

The ELISAs described here combine the special properties of antigen-antibody interactions with simple phase separations to produce powerful assays for detecting biological molecules. The multivalency of antibodies can result in the formation of long-lived antigen-antibody complexes, thus allowing long periods of time during which such complexes can be measured. By designing an assay so that a capture reagent initiates the binding of antigen-antibody complexes and enzyme conjugates onto a solid phase, the unbound reagents can be easily and rapidly separated from the solid phase. The solid phase is washed and the

amount of bound conjugate is visualized by incubating the solid phase with a substrate that forms a detectable product when hydrolyzed by the bound enzyme. ELISAs are similar in principle to radioimmunoassays, except that the radioactive label is replaced by an enzyme conjugate.

A number of different enzymes have been successfully used in ELISAs, including alkaline phosphatase, horseradish peroxidase, β -galactosidase, glucoamylase, and urease. Alkaline phosphatase—perhaps the most widely used conjugated enzyme—is recommended because of its rapid catalytic rate, excellent intrinsic stability, availability, ease of conjugation, and resistance to inactivation by common laboratory reagents. Additionally, the substrates of alkaline phosphatase are nontoxic and relatively stable. Solutions of *p*-nitrophenyl phosphate (NPP) are stable for months at 4°C, while solutions of 4-methylumbelliferyl phosphate (MUP) can be kept for months at room temperature without any significant spontaneous hydrolysis. The biggest disadvantage of alkaline phosphatase is that if NPP is used as a substrate, the yellow color of the nitrophenyl product is relatively difficult to detect visually. Using the substrate MUP instead of NPP can greatly enhance the sensitivity of the assay. The fluorogenic system using MUP is 10 to 100 times faster than the chromogenic system using NPP, and appears to be as sensitive as an enhanced chromogenic assay in which alkaline phosphatase generates NAD⁺ from NADP (Macy et al., 1988). The disadvantage of using fluorogenic substrates is that they require a microplate fluorometer costing twice as much as a high-quality microtiter plate spectrophotometer.

Cellular ELISAs have been shown to be as sensitive as flow cytometry analysis in detecting some cell-surface antigens (Bartlett and Noelle, 1987) and are potentially of great value in rapidly screening hybridoma supernatants for antibodies against surface molecules (Feit et al., 1983). Using ELISAs for screening large numbers of hybridoma supernatants has been hindered by the large number of cells required and high background signal. The increased sensitivity of the fluorogenic system should reduce the number of cells needed by a factor of 5, making the system more useful as a screening assay.

In addition to the methods described here, hundreds of other ELISA applications have been described, including the determination of

antibody affinities (Beatty et al., 1987; Schots et al., 1988), the detection of antibodies specific for hormone receptors (Quinn et al., 1988; Wang and Leung, 1985), expression cloning of lymphokine receptors (Harada et al., 1990), and homogeneous assays in which a solid phase is not needed because the antigen-antibody interaction itself modifies the enzymatic activity (Rubenstein et al., 1972). A number of books are devoted to ELISAs and can be consulted for further discussion (Maggio, 1981; Kurstak, 1986).

Critical Parameters

Sensitive ELISAs require antibodies of high affinity and high specificity. Since the sensitivity of an ELISA depends upon the affinity of the antibodies involved, antibodies with the highest affinities should be used when setting up ELISAs. Antibodies should be screened for unwanted cross-reactions. For instance, capture antibodies must not bind conjugate antibodies and vice versa. There are many commercial sources of reliable reagents. *Linscott's Directory of Immunological and Biological Reagents* is an excellent source book for locating reagents used in ELISAs. If reagents from one source are inadequate, try another.

When screening for expressed proteins in *E. coli*, it is important to utilize conjugates with antibodies that recognize nonnative and native molecules. Many foreign proteins expressed in *E. coli* will not assume their native conformation, and expression of such proteins will not be detected if antibody specific for the native form is used. It is also important to test enzyme-antibody conjugates for cross-reactivity or nonspecific binding to host cell molecules. This potential problem can be eliminated by incorporating these as control antigens in the screening procedures used to select the original antibodies in the basic protocol.

When coating plates with antigen, the antigen preparation need not be pure, but should generally comprise >3% of the protein in the coating solution. In some situations, dilution of the antigen solution with BSA has greatly improved the sensitivity of the ELISA (Jitsukawa et al., 1989).

All steps after coating the microtiter plates should be carried out in solutions containing 0.05% Tween 20 and a carrier protein (0.25% BSA or gelatin).

When using ELISAs for quantitative determinations of antigen or antibody concentrations, four guidelines should be followed.

First, it is essential that all experimental conditions up to the final wash after incubation with conjugate—including incubation times, wash times, reagent concentrations, and temperature—be kept constant between experiments. This is especially important in assays using polyclonal antibodies and complex mixtures of antigens. The optimal concentrations of all reagents for each system should be determined in an initial criss-cross serial dilution experiment (see first support protocol). Second, because the efficiency of binding and other micro-environmental conditions can vary from plate to plate, a standard curve should be included on each plate. Third, all samples must be analyzed at least in duplicate. Fourth, the concentration of the reagent being quantitated must lie within the dynamic range of the standard curve.

Anticipated Results

Antibody-sandwich assays are generally the most sensitive ELISA configuration and can detect concentrations of protein antigens between 100 pg/ml and 1 ng/ml. ELISAs in which antigen is directly bound to plates are usually an order of magnitude less sensitive than sandwich techniques.

Either the direct or sandwich ELISA may be used to detect and quantitate a bacterially expressed antigen or a purified or partially purified antigen in the range of 1 ng/ml to 1 µg/ml. A major disadvantage of the direct ELISA is that when an impure antigen preparation like a bacterial lysate is coated directly onto the surface of the microtiter well, the antigen must compete with all the other macro-molecules in the lysate for binding to the plastic and very little of the desired antigen may be bound. The sandwich ELISA bypasses this problem by relying on selective adsorption of an antigen to an antigen-specific antibody-coated surface.

Time Considerations

These assays are designed to take ~6 hr, but the incubation times may be abbreviated or expanded as needed. Since equilibrium binding between the soluble and solid phases frequently takes 5 to 10 hr, stronger specific signals can usually be obtained by longer incubations.

Fluorogenic ELISAs are generally 10 to 100 times faster than assays using chromogenic substrates.

Literature Cited

- Bartlett, W.C. and Noelle, R.J. 1987. A cell-surface ELISA to detect interleukin 4-induced class II MHC expression on murine B cells. *J. Immunol. Methods* 105:79-85.
- Beatty, J.D., Beatty, B.G., and Vlahos, W.G. 1987. Measurement of monoclonal affinity by non-competitive immunoassay. *J. Immunol. Methods* 100:173-179.
- Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., and Strober, W., eds. 1991. Current Protocols in Immunology, Chapter 5: Immunofluorescence and cell sorting. Greene Publishing and Wiley-Interscience, New York.
- Engvall, E. and Perlman, P. 1971. Enzyme-linked immunosorbent assay (ELISA): Quantitative assay of immunoglobulin G. *Immunochemistry* 8:871-879.
- Feit, C., Bartal, A.H., Tauber, G., Dymbort, G., and Hirshaut, Y. 1983. An enzyme-linked immunosorbent assay (ELISA) for the detection of monoclonal antibodies recognizing antigens expressed on viable cells. *J. Immunol. Methods* 58:301-308.
- Harada, N., Castle, B.E., Gorman, D.M., Itoh, N., Schreurs, J., Barrett, R.L., Howard, M., and Miyajima, A. 1990. Expression cloning of a cDNA encoding the murine interleukin 4 receptor based on ligand binding. *Proc. Natl. Acad. Sci. U.S.A.* 87:857-861.
- Jitsukawa, T., Nakajima, S., Sugawara, I., and Watanabe, H. 1989. Increased coating efficiency of antigens and preservation of original antigenic structure after coating in ELISA. *J. Immunol. Methods* 116:251-257.
- Kurstak, E. 1986. Enzyme Immunodiagnosis. Academic Press, San Diego.
- Linscott's Directory of Immunological and Biological Reagents, Santa Rosa, Calif.
- Macy, E., Kemeny, M., and Saxon, A. 1988. Enhanced ELISA: How to measure less than 10 picograms of a specific protein (immunoglobulin) in less than 8 hours. *FASEB J.* 2:3003-3009.
- Maggio, E.T. 1981. Enzyme Immunoassay. CRC Press, Boca Raton, Fla.
- Quinn, A., Harrison, R., Jehanli, A.M.T., Lunt, G.G., and Walsh, S.S. 1988. An ELISA for the detection of anti-acetylcholine receptor antibodies using biotinylated α -bungarotoxin. *J. Immunol. Methods* 107:197-203.
- Rubenstein, K.E., Schneider, R.S., and Ulmann, E.L. 1972. Homogeneous enzyme immunoassay: A new immunochemical technique. *Biochem. Biophys. Res. Commun.* 47:846.
- Schots, A., Van der Leede, B.J., De Jongh, E., and Egberts, E. 1988. A method for the determination of antibody affinity using a direct ELISA. *J. Immunol. Methods* 109:225-233.

Wang, K.C. and Leung, B.S. 1985. Fluorometric ELISA methods for rapid screening of anti-estrogen receptor antibody production in hybridoma cultures. *J. Immunol. Methods* 84:279.

Key Reference

Linscott's Directory. See above.

Highly recommended publication listing sources of immunological reagents, kits, and cells/organisms, including addresses and phone numbers of commercial suppliers (updated quarterly).

Contributed by Peter Hornbeck
University of Maryland
Baltimore, Maryland

Scott E. Winston (bacterial cell lysate antigens)
Univax Biologics
Rockville, Maryland

Steven A. Fuller (bacterial cell lysate antigens)
Allelix Inc.
Mississauga, Ontario